EXACT Therapeutics

EXTX

NO0010852213

Biotechnology & Medical Research

Market Closed - Oslo Bors Other stock markets 10:45:00 2024-04-23 am EDT			5-day change	1st Jan Change
7 ^NOK	0.00%		+2.94%	-41.67%

Apr. 19	EXACT Therapeutics AS Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Exact Therapeutics Wins Regulatory Approvals for Patient Recruitment in Dose Expansion Study	MT

EXACT THERAPEUTICS : ANNOUNCES INNOVATIVE PROBE DEVELOPMENT COLLABORATION WITH GE HEALTHCARE

January 20, 2021 at 02:01 am EST

OSLO/LONDON, JANUARY 20 2021: EXACT THERAPEUTICS AS ("EXACT-Tx" or the
"Company"), a clinical stage precision medicine company today announced a
collaboration with GE Healthcare to develop an innovative ultrasound probe to be
used in forthcoming studies using Acoustic Cluster Therapy (ACT®) across
multiple disease conditions. 

"We are delighted to collaborate with GE Healthcare, a leader in the field of
diagnostic imaging and ultrasound. We look forward to working closely with GE
Healthcare in developing an innovative ultrasound probe with the goal of
enabling effective deployment of the ACT® therapeutic amplification platform
across indications for our forthcoming phase II clinical development program",
said Dr Rafiq Hasan, CEO of EXACT Therapeutics AS. 

ACT® is a proprietary formulation consisting of microbubbles and microdroplets
that are activated through the application of ultrasound with the consequent
increase in targeted delivery of a co-administered therapeutic agent.  ACT® is
supported by a strong and broad preclinical package demonstrating therapeutic
enhancement in multiple oncology models (pancreatic, breast, colon, prostate) as
well as controlled blood-brain barrier opening. Currently ACT® is being
evaluated in the international ACTIVATE Phase I clinical trial in patients with
metastatic colorectal and pancreatic cancer at the Royal Marsden Hospital in
London. 


About EXACT
EXACT-Tx is a clinical stage Norwegian biotech company developing a technology
platform for targeted therapeutic enhancement - Acoustic Cluster Therapy (ACT®).
ACT® sonoporation is a unique approach to ultrasound-mediated, targeted drug
enhancement - with the potential to significantly amplify the clinical utility
of a wide range of therapeutic agents across a multitude of indications
including within oncology (chemotherapy, immunotherapy), infectious diseases,
and neurological conditions. www.exact-tx.com


For more information contact:

Dr Rafiq Hasan
CEO EXACT Therapeutics 
Rafiq@exact-tx.com

Richard Hayhurst/Janet Joy
Tel +44 7711 821527
richard@rhapr.eu

Click here for more information

Latest news about EXACT Therapeutics

EXACT Therapeutics AS Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 18	CI
Exact Therapeutics Wins Regulatory Approvals for Patient Recruitment in Dose Expansion Study	23-10-31	MT
EXACT Therapeutics AS Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-28	CI
EXACT Therapeutics AS Announces Appointment of Caspar Foghsgaard as SVP Commercial & Business Development Effective 1 November 2023	23-09-27	CI
Exact Therapeutics Jumps 13% After Positive Outcomes From Acoustic Cluster Therapy Trial	23-09-26	MT
EXACT Therapeutics Announces Positive Clinical Results from the Activate Phase I Dose Escalation	23-09-25	CI
Exact Therapeutics, Cordance Medical to Collaborate on Drug Delivery Solutions for Brain Treatment	23-09-06	MT
EXACT Therapeutics and Cordance Medical Announce Strategic Partnership to Revolutionize Drug Delivery to the Brain	23-09-05	CI
Exact Therapeutics Concludes Dose Escalation Under Cancer Therapy Study	23-08-07	MT
EXACT Therapeutics Completes the Dose Escalation Part of ACTIVATE Study	23-08-06	CI
EXACT Therapeutics AS Receives Regulatory Approval to Start the Dose Expansion Part of ACTIVATE Study	23-07-31	CI
EXACT Therapeutics AS Announces Management Changes	23-06-09	CI
EXACT Therapeutics AS Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-21	CI
EXACT THERAPEUTICS AS Presents Encouraging Clinical Case Report Data At Science & Technology Event	23-03-27	CI
Exact Therapeutics Gets UK Clearance to Reopen Phase 1 Acoustic Cluster Therapy Trial	23-02-02	MT
Exact Therapeutics Receives Regulatory Approval to Reopen the Activate Clinical Trial	23-02-02	CI
Norway's Exact Therapeutics Wins NOK16 Million Grant for Cancer Therapy Research; Shares Tumble 24%	22-12-22	MT
Norwegian Research Council Awards EXACT Therapeutics AS Exact-Tx NOK 16 Million to Support the Research of Immunotherapy Responses in Solid Tumours with Acoustic Cluster Therapy	22-12-22	CI
EXACT Therapeutics AS And Tgen Publish Preclinical Data On Acoustic Cluster Therapy Combined With Chemotherapy In A Pancreatic Cancer Model	22-11-22	CI
EXACT Therapeutics AS Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-21	CI
EXACT Therapeutics Appoints Chief Medical Officer	22-09-16	MT
EXACT Therapeutics AS Announces Appointment of Amir Snapir as Chief Medical Officer, Effective 21 September 2022	22-09-15	CI
Norway's Exact Therapeutics Appoints New CFO	22-08-31	MT
EXACT Therapeutics AS Appoints John Edminson as Chief Financial Officer, Effective 1 October 2022	22-08-30	CI
Exact Therapeutics, GE Secure $1.6 Million Norwegian Grant for Ultrasound Imaging, Therapy Project	22-06-23	MT

Exact Therapeutics AS is a Norway-based clinical-stage biopharmaceutical company, which develops ultrasound-mediated technology platform for targeted therapeutic enhancement Acoustic Cluster Therapy (ACT). ACT sonoporation is an approach to ultrasound-mediated, targeted drug enhancement with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within cancer (chemotherapy, immunotherapy), infectious diseases, and neurological conditions. The Company's purpose is to extend and enrich patient lives through targeted therapeutic enhancement. It is done through harnessing the power of ultrasound in combination with ACT formulation.

Sector

Biotechnology & Medical Research

Calendar

2024-04-23 - Q4 2023 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
EXACT THERAPEUTICS	-41.67%	20.35M
IQVIA HOLDINGS INC.	+2.86%	42.11B
LONZA GROUP AG	+48.83%	40.08B
MODERNA, INC.	+8.39%	40B
CELLTRION, INC.	-10.82%	26.87B
ICON PUBLIC LIMITED COMPANY	+7.82%	24.58B
ALNYLAM PHARMACEUTICALS, INC.	-23.68%	18.44B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.60%	11.94B
MEDPACE HOLDINGS, INC.	+32.21%	11.66B
UNITED THERAPEUTICS CORPORATION	+7.29%	11.01B